我要投票 巨仁堂在连锁药店行业中的票数:146
· 外 推 电 报 ·
2025-03-09 23:40:02 星期日

【巨仁堂是哪个国家的品牌?】

巨仁堂是什么牌子?吉林巨仁堂药业股份有限公司,座落在药材宝库长白山南麓、浑江之畔、风景秀丽的通化市。公司始建于1975年,厂区占地面积4.5万平方米,建筑面积20000平方米,公司现有职工278人,营销人员1500多人

外推网助力巨仁堂品牌出海!通过在本页面挂载巨仁堂品牌的产品链接和联系邮箱,可以提高巨仁堂产品曝光!跨境电商爆单神器,目前只要100元/年哦~

吉林巨仁堂药业股份有限公司,座落在药材宝库长白山南麓、浑江之畔、风景秀丽的通化市。公司始建于1975年,厂区占地面积4.5万平方米,建筑面积20000平方米,公司现有职工278人,营销人员1500多人,营销网络遍布全国30个省,是一家集科研、生产、销售为一体的制药企业。她以技术力量强大,工艺设备先进,品种好又多,发展资金雄厚等优势,在医药舞台上发挥着越来越重要的作用。 

由于地处长白山,占有得天独厚的地理位置和资源优势,其产品采用长白山天然名贵药材精制而成,产品质量好,疗效高,深得广大患者信赖。公司总经理董起毓带领公司全体员工艰苦创业、诚信经营、以人为本、科技创新、开拓发展,通过创新企业管理机制、经营机制,开拓市场,开发新产品,大胆聘用制药人才,与科研部门合作,从而带出了一支有凝聚力的高素质企业队伍。  

2002年,企业筹集资金14500万元,进行GMP改造,2004年1月顺利通过达标验收,建成颗粒剂、丸剂、胶囊剂三个剂型的大型现代化制药企业,使企业的整体形象、生产能力大为改观,企业迈上了快速发展的轨道。在企业不断发展壮大的形势下,企业经济效益逐年提高,由于销量上升过快,2004年企业又筹集资金13500多万元,对丸剂、水蜜丸、口服液、糖浆剂进行GMP改造,2004年12月27日顺利通过国家GMP认证。两期GMP改造的成功认证,使企业的生产设施和产品质量已经达到国内领先的高科技水平。  

目前,已上市的产品有10个系列,共计38个品种,为企业的长足发展奠定了基础。 

多年来,企业利用地理资源优势,以严格的企业管理,与时俱进的工作精神,不断开拓市场,开展企业文化,来鼓舞人,激励人,凝聚人。公司生产的巨焱消牌炎立消胶囊(出口名称:CLOVERY)已获得出口资质,即已获得美国FDA认证和加拿大DIN认证。  

为确保出口产品重金属含量合格,保证出口产品的质量和数量,目前公司正在建设绿色中药材GAP生产基地,公司引进了先进的生产提取设备,建设了现代化的标准出口生产车间。绿色中药材GAP生产基地项目投产后,可年产中药材545吨,可满足本企业的需求。 

多年来,企业利用地理资源优势,以严格的企业管理,与时俱进的工作精神,不断开拓市场,增强效益。并获得了“纳税大户”、“重合同守信用企业”、“先进企业”、“重点保护单位”、“高新技术企业”等荣誉称号。巨仁堂药业正以稳健的脚步,踏上快速发展的轨道,去迎接并战胜更大的挑战。


英文翻译:Jilin jurentang Pharmaceutical Co., Ltd. is located in Tonghua City, which is located at the south foot of Changbai Mountain, Hunjiang River and has beautiful scenery. Founded in 1975, the company covers an area of 45000 square meters and a building area of 20000 square meters. The company has 278 employees and more than 1500 marketing personnel. Its marketing network covers 30 provinces in China. It is a pharmaceutical enterprise integrating scientific research, production and sales. She plays a more and more important role in the pharmaceutical stage with the advantages of strong technical force, advanced technology and equipment, good variety and abundant development funds. Because it is located in Changbai Mountain, it has a unique geographical location and resource advantage. Its products are refined from Changbai Mountain's natural and precious medicinal materials, with good quality and high curative effect, which are trusted by the majority of patients. Dong Qiyu, general manager of the company, led all employees of the company to work hard, operate in good faith, put people first, innovate in science and technology, develop and develop. By innovating enterprise management mechanism and operation mechanism, the company opened up market, developed new products, boldly employed pharmaceutical talents, and cooperated with scientific research departments, thus bringing out a cohesive high-quality enterprise team. In 2002, the enterprise raised 14.5 million yuan to carry out GMP transformation. In January 2004, the enterprise successfully passed the standard acceptance and built a large-scale modern pharmaceutical enterprise with three dosage forms of granules, pills and capsules, which greatly improved the overall image and production capacity of the enterprise and put it on the track of rapid development. Under the situation of continuous development and growth of the enterprise, the economic benefit of the enterprise has been improved year by year. Due to the rapid increase of sales volume, the enterprise raised more than 135 million yuan in 2004 to carry out GMP transformation of pills, honey pills, oral liquid and syrup, and successfully passed the national GMP certification on December 27, 2004. The successful certification of two phases of GMP transformation has made the production facilities and product quality of the enterprise reach the leading high-tech level in China. At present, there are 10 series of products on the market, 38 varieties in total, which lays the foundation for the rapid development of the enterprise. Over the years, enterprises have been using the advantages of geographical resources, strict enterprise management, working spirit of keeping pace with the times, constantly opening up markets, developing corporate culture, to inspire, inspire and unite people. The juyanxiao brand Yanlixiao capsule (export name: clovery) produced by the company has obtained export qualification, i.e. FDA certification in the United States and din certification in Canada. In order to ensure that the heavy metal content of export products is qualified and the quality and quantity of export products are guaranteed, the company is currently building a gap production base for green Chinese herbal medicines. The company has introduced advanced production extraction equipment and built a modern standard export production workshop. After the production base project of green Chinese herbal medicine GAP is put into production, the annual output of Chinese herbal medicine can reach 545 tons, which can meet the needs of the enterprise. Over the years, the enterprise has made use of the advantages of geographical resources, with strict enterprise management and the working spirit of keeping pace with the times, to continuously open up the market and enhance efficiency. It has also won the honorary titles of "big tax payer", "enterprise abiding by contracts and keeping promises", "advanced enterprise", "key protection unit" and "high and new technology enterprise". Jurentang pharmaceutical industry is stepping on the track of rapid development with steady steps to meet and overcome greater challenges.

本文链接: https://www.waitui.com/brand/991856d39.html

千城特选小程序码

7×24h 快讯

2连板国脉科技:公司现已完成部分居家养老场景AI智能体的原型开发 相关技术成果尚未形成商业化收入

36氪获悉,国脉科技(002093.SZ)发布股票交易异常波动公告称,公司关注到部分媒体将公司列为AI智能体(AI Agent)核心龙头股。公司基于在身联网、智慧康养领域的技术积累,现已完成部分居家养老场景AI智能体(AI Agent)的原型开发,目前产品正处于场景适配度优化和用户体验提升阶段,相关技术成果尚未形成商业化收入,短期不会对公司经营业绩产生重大影响。敬请广大投资者关注技术转化周期风险,理性判断投资价值。

2小时前

我国近半地区提前实现2025年宫颈癌筛查目标

《中国疾病预防控制中心周报》近日公布了2023至2024年我国女性宫颈癌筛查率数据,35至64岁女性的整体筛查率超过50%。2023年,国家卫健委等10部门发布《加速消除宫颈癌行动计划(2023—2030年)》,设定了“到2025年我国适龄妇女宫颈癌筛查覆盖率达到50%、到2030年达到70%”的目标。2023至2024年,中国疾控中心团队在31个省份开展了宫颈癌筛查率调查。结果显示,35至64岁女性的筛查率达到51.5%,20岁及以上女性的筛查率为36.8%。35至64岁女性的整体筛查率已提前实现2025年目标。同时,我国接近一半的地区已提前实现2025年目标。农村筛查覆盖率为48.2%,仍低于2025年目标。(财联社)

2小时前

中创新航:公司股份获纳入港股通证券名单

36氪获悉,中创新航在港交所公告,根据上交所发布的通知,公司股份已获纳入沪港通下的港股通标的证券名单,并于2025年3月10日起生效。公司董事会认为,公司股份获纳入港股通标的证券名单,将有助于扩大本公司的投资群体,提升公司股票的流动性和市场活跃度。

2小时前

汤姆猫:公司在AI业务上确立了“AI+IP+Agent”的业务发展方向

36氪获悉,汤姆猫(300459.SZ)发布投资者关系活动记录表公告称,公司在AI业务上确立了“AI+IP+Agent”的业务发展方向,围绕该业务发展方向,公司将从以下几个维度深入推进产品的研发与升级工作:在产品形象上,汤姆猫家族IP包含6个经典的IP角色形象,公司将尽快推出不同IP形象的AI情感陪伴机器人,以满足不同用户对不同IP形象的喜爱需求。基于在多模态技术架构、大模型驱动、任务规划逻辑等方面的深层次共性,公司将在生态协作、情感化任务执行等领域探索与其他AI Agent的结合,将大模型、数据、工具多维一体融合进公司的家庭智能硬件终端上,推动AI从单一功能向“全能伙伴”演进。公司也将与各类机器人相关产业方探讨更丰富的产品形态,例如便于携带的小型机器人、能够运动的机器人等,持续丰富产品形态矩阵,满足用户在不同场景下的使用需求。

2小时前

长春一东:一汽股权公司拟减持不超3%公司股份

36氪获悉,长春一东公告,一汽股权投资(天津)有限公司计划通过集中竞价交易和大宗交易方式减持公司股份合计不超过424.55万股,即不超过公司总股本的3%。

2小时前

本页详细列出关于百姓乐的品牌信息,含品牌所属公司介绍,百姓乐所处行业的品牌地位及优势。
咨询